The Phase XXIII C1 privacy mechanism achieved p99 round-trip latency of 0.20–0.25 ms and preserved clinical-grade decision quality (sensitivity 0.85-0.88) against 32 adversary variants.
The proposed bidirectional closed-loop privacy mechanism for bioelectric digital twins demonstrates low latency, preserves clinical decision quality, and defeats multiple adversary variants in computational validation.
This deposit contains the complete pre-registration corpus (embedded in section-batch runner scripts), runner code, summary verdicts, per-study reports, figures, POC addenda, master synthesis, and arXiv-format manuscript for a 168-study pre-registered empirical validation campaign of bidirectional closed-loop bioelectric digital-twin privacy across seven canonical closed-loop clinical applications: closed-loop deep brain stimulation (DBS), responsive neurostimulation (RNS) for drug-resistant epilepsy, closed-loop insulin pump, antitachycardia pacing in implantable cardioverter-defibrillators (ICDs), brain-computer interface (BCI) motor restoration, real-time neurofeedback, and closed-loop ventilation. The campaign comprises approximately 840 pre-registered hypothesis-testing decision rules across twelve thematic sections, executed under continuous deterministic protocol (PYTHONHASHSEED=0) with zero post-hoc threshold adjustments. The campaign extends companion Paper 10 (10.5281/zenodo.20480183, unidirectional release-only bioelectric privacy) to bidirectional closed-loop deployment. Key empirical findings: (i) the Phase XXIII C1 mechanism is closed-loop deployment-ready out of the box, with measured p99 round-trip latency 0.20–0.25 ms across all seven canonical applications and budget margins from 220× (BCI motor restoration, tightest budget) to 1.5 × 10⁶× (closed-loop insulin pump, loosest budget); (ii) clinical-grade decision quality is preserved on real PhysioNet ECG cohorts: CHB-MIT seizure detection sensitivity 0.88 / specificity 0.86, MIT-BIH arrhythmia detection sensitivity 0.85 / specificity 0.89, false-positive intervention rate ≤ 5%, false-negative intervention rate ≤ 5%; (iii) the mechanism defeats 32 distinct adversary variants with appropriate C2 mitigations (constant-time padding, cryptographically-signed nonces, OOD gating, rate limiting, decoy interventions, role-based access control, signed actuator-command verification, sensor attestation, separation-of-duties, quorum-based cohort-bound validation); (iv) compliance is substantively supported across fourteen regulatory standards (FMEA through FDA cybersecurity), with 25 gaps documented; (v) eleven explicit limitations are disclosed including multi-event-per-trial efficacy degradation, quantum-readiness gap, and the multi-session privacy-budget exhaustion inherited from Phase XXIII. The deposit includes 12 runner scripts covering all 168 studies (Studies 301–468), 168 JSON summary verdicts, 168 per-study reports, 8 figures, a comprehensive POC summary document with full hypothesis tables, the Phase XXIV scope and progress synthesis, and the v3 polished manuscript (markdown + two-column IEEE arXiv-format Word and PDF). All studies reproduce bit-identically under PYTHONHASHSEED=0 with the pinned numpy 1.26.x / scipy 1.11.x / scikit-learn 1.4.x / PyWavelets 1.5.x / wfdb 4.1.x / pandas 2.1.x dependency stack. All input data are publicly available from PhysioNet (https://physionet.org) under the ODC-By license. Released under CC-BY 4.0.
Ferlic et al. (Mon,) führten eine andere Studie zu bioelektrischen digitalen Zwillingsanwendungen (z.B. Epilepsie, Arrhythmie) durch. Der bidirektionale geschlossene Datenschutzmechanismus (Phase XXIII C1) wurde gegenüber 32 verschiedenen Angreifervarianten hinsichtlich der Rundentripp-Latenz und der Entscheidungsqualität (Sensitivität/Spezifität) bewertet. Der Datenschutzmechanismus von Phase XXIII C1 erreichte eine p99-Rundentripp-Latenz von 0,20–0,25 ms und bewahrte die klinische Entscheidungsqualität (Sensitivität 0,85-0,88) gegenüber 32 Angreifervarianten.